1. HBW Insight
  2. >>Geography
  3. >>International

Plant-Based Smoking Cessation Alternative Cytisine ‘Likely’ To Help Quitters

 
• By David Ridley

“Moderate-certainty evidence” shows that low-cost smoking cessation therapy cytisine “probably” helps more people to quit smoking than a placebo and “low-certainty evidence” suggests that the natural alternative may also help more people to quit than using a nicotine replacement monotherapy, finds a recently published Cochrane Review.

Smoking_Cessation
• Source: Shutterstock

Naturally-derived smoking cessation alternative cytisine is “likely” to help more people to quit smoking than if they were to receive no medical help, says a recently published Cochrane Review.

Currently available OTC in several countries in central and eastern Europe, as well as Canada, cytisine may even help more...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

Over The Counter: EU Omnibus And ESG, What You Need To Know, With CEN Group’s Jasper Crone

 
• By David Ridley

HBW Insight catches up with sustainability expert Jasper Crone to find out what consumer health companies need to know about the European Commission's Omnibus simplification package.

AESGP Annual Meeting: European OTC Market Outlook ‘Very Positive’ Thanks To Prevention Trend

 
• By David Ridley

The European OTC market grew at double the rate of the global market in the last twelve months, according to IQVIA Consumer Health, driven by a long-term trend for prevention. Consultancy Simon Kucher identifies a desire to live a longer, healthier life as the primary concern behind this trend.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By David Ridley

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.